logo
  Join        Login             Stock Quote

Achillion Pharmaceuticals (ACHN) Posts Wider-Than-Expected Q3 Loss

 November 08, 2012 08:01 AM
 


(By Balaseshan) Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) reported a wider-than-expected loss in the third quarter due to costs incurred from clinical testing of its hepatitis C virus protease inhibitors.

Loss for the third quarter widened to $15.26 million or $0.20 per share from $10.44 million or $0.15 per share.

The company recognized no revenue for the third quarter, compared to about $64,000 last year.

Analysts, on average, polled by Thomson Reuters had expected a loss of $0.17 per share on revenue of $50,000 for the third quarter.

Research and development expenses increased to $12.6 million from $8.6 million, primarily due to increased expenses related to preclinical and clinical testing of ACH-3102, partially offset by decreased clinical trial expenses for sovaprevir, ACH-2684 and ACH-2928.

[Related -Insider Buying Achillion Pharmaceuticals, Inc. (ACHN) On The Verge Of FDA News And Technical Breakout?]

General and administrative expenses for the third quarter rose to $2.6 million from $1.9 million.

"Furthermore, with our strengthened balance sheet and continued progress with sovaprevir, our next-generation protease inhibitor, we believe that we are poised to begin all-oral, interferon-free combination studies evaluating our proprietary agents for the treatment of hepatitis C virus or HCV in the coming months," said Michael Kishbauch, Chief Executive of Achillion.

ACHN closed Wednesday's regular trading down 4.16% at $8.75. The stock has been trading between $5.12 and $12.95 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageOld Bank's New Breakout has Big Rally Potential

One of my favorite things to see in a long candidate is a pattern of beating Wall Street's earnings read on...

article imageIs The Stock Market's 5-Year Return A Useful Proxy For Valuation?

Tobin’s Q, a market-valuation metric, is back in the news, in part thanks to a widely read Bloomberg read on...

article image4 Dogs To Sell Immediately

Despite the chorus of analysts and investors calling for the long-awaited correction, the market is showing read on...

article imageThe Fed's Magical Mystery Tour

What's going on at the Fed? Notorious dove, Charles Evans of the Chicago Fed, gave a speech in read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

A Snapback And 50% Retracement
More Articles on: Medical



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.